Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

ClinicalTrials.gov public records Last synced May 22, 2026, 12:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–4 of 4 matching trials from the live ClinicalTrials.gov search.

Local D1 index available.

Filters: Condition: Secondarily Generalized Seizures Clear all

Withdrawn Phase 2 Interventional

GW273225 Therapy Added To Current Seizure Treatments In Patients With Partial Seizures

NCT00567424

View directory record Official record

Conditions: Epilepsy
Interventions: GW273225; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older

Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 30
States / cities: Phoenix, Arizona • Sun City, Arizona • Little Rock, Arkansas + 26 more

Source: ClinicalTrials.gov public record

Updated Apr 3, 2013 · Synced May 22, 2026, 12:34 AM EDT

Completed Phase 2 Interventional Results available

A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.

NCT00175825

View directory record Official record

Conditions: Epilepsy
Interventions: Placebo, Brivaracetam; Other · Drug
Lead sponsor: UCB Pharma; Industry
Eligibility: 16 Years to 65 Years

Enrollment: 210 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 26
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Fresno, California + 23 more

Source: ClinicalTrials.gov public record

Updated Oct 1, 2018 · Synced May 22, 2026, 12:34 AM EDT

Completed Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of Perampanel as Monotherapy or First Adjunctive Therapy in Subjects With Partial Onset Seizures With or Without Secondarily Generalized Seizures or With Primary Generalized Tonic-Clonic Seizures

NCT03288129

View directory record Official record

Conditions: Partial Onset Seizures, Secondarily Generalized Seizures, Primary Generalized Tonic-Clonic Seizures
Interventions: Perampanel; Drug
Lead sponsor: Eisai Inc.; Industry
Eligibility: 4 Years and older

Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 24
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 20 more

Source: ClinicalTrials.gov public record

Updated May 15, 2022 · Synced May 22, 2026, 12:34 AM EDT

Completed Phase 2 Interventional Results available

Study With Seletracetam (Ucb 44212) in Adult Subjects (18 to 65 Years) With Partial Onset Seizures

NCT00152451

View directory record Official record

Conditions: Epilepsy, Partial
Interventions: Seletracetam (ucb 44212); Drug
Lead sponsor: UCB S.A. - Pharma Sector; Industry
Eligibility: 18 Years to 65 Years

Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 7
States / cities: Little Rock, Arkansas • San Francisco, California • Stanford, California + 4 more

Source: ClinicalTrials.gov public record

Updated Mar 28, 2024 · Synced May 22, 2026, 12:34 AM EDT